INT230634

Context Info Confidence 0.43 First Reported 2008 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 10 Total Number 10 Disease Relevance 1.03 Pain Relevance 0.46

cytosol (POU5F1) nucleoplasm (POU5F1) nucleus (POU5F1) DNA binding (POU5F1) transcription factor binding (POU5F1) cytoplasm (POU5F1)

Anatomy Link Frequency neuronal 1 endometrium 1 neural 1 POU5F1 (Homo sapiens)

Pain Link Frequency Relevance Heat Action potential 24 100.00 anesthesia 4 90.08 Sciatic nerve 12 87.92 Serotonin 2 80.96 Glutamate 9 79.04 gABA 10 77.16 antagonist 8 70.48 Inflammation 51 50.00 Central nervous system 7 11.68 Spinal cord 32 5.00

Disease Link Frequency Relevance Heat Endometriosis (extended) 5 100.00 Hypoxia 71 93.16 Keloid Scars 103 86.08 Injury 21 82.08 Wound Healing 6 71.84 Osteoporosis 4 60.56 Neurodegenerative Disease 11 52.28 INFLAMMATION 54 50.00 Cancer 35 50.00 Obesity 22 50.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

This rejects our study hypothesis that OCT-4 is overexpressed during endometrial proliferation in the follicular phase and downregulated during the secretory transformation of the endometrium in the luteal phase.

Negative_regulation (downregulated) of OCT-4 in endometrium associated with endometriosis (extended)

1) Confidence 0.43 Published 2010 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2867815 Disease Relevance 0.10 Pain Relevance 0

GF-iPS-3F showed a greater decrease in the CpG methylation ratio in the promoter regions of Nanog and Oct3/4 in comparison to GF-iPS-4F cells that resulted in a methylation pattern similar to that of mouse ES cells.

Negative_regulation (decrease) of Oct3

2) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2939066 Disease Relevance 0 Pain Relevance 0

MiRNAs highly differentially expressed in Oct4/ATSCs were as follows; let 7, mir 170, mir 132 (upregulated in Oct4/ATSCs) and let 17 and let 120 (downregulated in Oct4/ATSCs).

Negative_regulation (downregulated) of Oct4

3) Confidence 0.39 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2747014 Disease Relevance 0.06 Pain Relevance 0

Electrophysiological evaluation (evoked action potential of engrafted Oct4/ATSCs was performed before, immediately after and 30 days after the sciatic taxonomy and Oct4/ATSCs transplantation.

Negative_regulation (evaluation) of Oct4 associated with action potential

4) Confidence 0.38 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2747014 Disease Relevance 0 Pain Relevance 0.28

siRNA transfection prominently induced downregulated stemness genes expression, such as Rex1, Sox2, Oct4, and Klf4 with prominent growth attenuation (Figure 3E, 3F).

Negative_regulation (downregulated) of Oct4

5) Confidence 0.35 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2817727 Disease Relevance 0.49 Pain Relevance 0

This Oct4 methylation pattern was more or less downregulated in the de-ATSC (5th region, 71.4%, 7th region, 36.5%) as compared to the control ATSC (5th region, 68.0%; 7th region, 30%; Figure 2D).

Negative_regulation (downregulated) of Oct4

6) Confidence 0.31 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2817727 Disease Relevance 0.24 Pain Relevance 0

Specifically, a gradual strong down-regulation of pluripotency markers OCT4 and REX1 was observed, accompanied by up-regulation of human neuronal markers PAX6, SOX1, NCAM and MAP2 (Figure 1E).

Negative_regulation (trong down-regu) of OCT4 in neuronal

7) Confidence 0.29 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2346555 Disease Relevance 0 Pain Relevance 0.12

Under control conditions, hESCs can be readily converted to neural cells over 16 days (Fig. 1A) with concomitant loss of pluripotency markers OCT4 and NANOG, and up regulation of neural progenitor markers MUSASHI (D8) and SOX1 (D 16).

Negative_regulation (loss) of OCT4 in neural

8) Confidence 0.15 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2752165 Disease Relevance 0.05 Pain Relevance 0.04

Treatment with IL-6 neutralizing antibody decreased the basal level of hTERT and Oct-4, and in conjunction with IL-17 antibody only slightly augmented the blockade of hTERT and Oct-4 expression in both SKPs and KPCs (Figure 5C).

Negative_regulation (decreased) of Oct-4

9) Confidence 0.13 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2771422 Disease Relevance 0.09 Pain Relevance 0

By comparison, addition of the activin/nodal receptor kinase (ALK4/5/7) inhibitor SB431542 results in accelerated loss of OCT4 and NANOG by D4, and gain of both MUSASHI (D4) and SOX1 (D8, Fig. 1B).

Negative_regulation (loss) of OCT4

10) Confidence 0.11 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2752165 Disease Relevance 0 Pain Relevance 0.03

General Comments

This test has worked.